Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-11-25
|
| pubmed:abstractText |
To evaluate the results, prognostic factors and especially side-effects of the treatment for subdiaphragmatic Hodgkin's disease (SHD) a retrospective study was conducted in the Haematology Departments and in the Cancer Centres of Nancy and Strasbourg between 1976 and 1990; 55 patients corresponding to the IA to IIB SHD stages were analysed. The median age was 45 years. In accordance with Ann Arbor classification, we observed 12 CS IA (21.3%), 2 CS IB (3.5%), 14 CS IIA (25.4%) and 27 CS IIB (49.7%). Twenty-five patients (45.4%) underwent laparotomy with spleen involvement in 10 cases. Fifteen patients (27.3%) had exclusive radiotherapy, 10 by inverted-Y field with or without splenic field, 5 by limited field to inguinal and homolateral iliac nodes. Forty patients had prior chemotherapy, 18 by MOPP protocol, 18 by hybrid MOPP/ABVD protocol and 4 by other schemes. The total dose delivered ranged from 26 to 45 Gy. With a median follow-up of 8 years, the overall and disease specific survival rates are respectively 61% and 83% at 10 years. Nine patients relapsed (16.4%), 4 among the 15 (26.6%) treated by exclusive irradiation and 5 among the 40 (12.5%) treated by combined therapy. We observed 8.3%, 21.4% and 18.5% of relapses respectively among the clinical stages IA, IIA and IIB. Eleven patients (20%) developed a second cancer. Twenty-six long-term complications were noted, nine of which concerned the digestive system. The only significant prognostic factor is age, with 10-year specific survival rates of 96% and 66% respectively for patients younger and older than 50 years (p=0.0003). Our data confirm that the most appropriate treatment for stage IA is exclusive radiotherapy and combined therapy for all other cases. With the use of CT-scan and eventually lymphography, the laparotomy is reserved only for cases with an uncertain diagnosis. Tobacco use is also clearly a risk factor in our series for late vascular complications and second cancers.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Mechlorethamine,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1021-335X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1513-8
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:9769397-Adolescent,
pubmed-meshheading:9769397-Adult,
pubmed-meshheading:9769397-Aged,
pubmed-meshheading:9769397-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9769397-Bleomycin,
pubmed-meshheading:9769397-Child,
pubmed-meshheading:9769397-Child, Preschool,
pubmed-meshheading:9769397-Cisplatin,
pubmed-meshheading:9769397-Dacarbazine,
pubmed-meshheading:9769397-Diaphragm,
pubmed-meshheading:9769397-Disease-Free Survival,
pubmed-meshheading:9769397-Doxorubicin,
pubmed-meshheading:9769397-Etoposide,
pubmed-meshheading:9769397-Female,
pubmed-meshheading:9769397-Follow-Up Studies,
pubmed-meshheading:9769397-France,
pubmed-meshheading:9769397-Hodgkin Disease,
pubmed-meshheading:9769397-Humans,
pubmed-meshheading:9769397-Incidence,
pubmed-meshheading:9769397-Male,
pubmed-meshheading:9769397-Mechlorethamine,
pubmed-meshheading:9769397-Middle Aged,
pubmed-meshheading:9769397-Neoplasm Staging,
pubmed-meshheading:9769397-Neoplasms, Second Primary,
pubmed-meshheading:9769397-Prednisone,
pubmed-meshheading:9769397-Procarbazine,
pubmed-meshheading:9769397-Prognosis,
pubmed-meshheading:9769397-Radiotherapy,
pubmed-meshheading:9769397-Radiotherapy Dosage,
pubmed-meshheading:9769397-Retrospective Studies,
pubmed-meshheading:9769397-Splenic Neoplasms,
pubmed-meshheading:9769397-Survival Rate,
pubmed-meshheading:9769397-Time Factors,
pubmed-meshheading:9769397-Vinblastine,
pubmed-meshheading:9769397-Vincristine
|
| pubmed:articleTitle |
Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
|
| pubmed:affiliation |
Department of Radiotherapy, Centre Paul Strauss, 67085 Strasbourg Cedex, France.
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|